Allurion Technologies (NYSE:ALUR) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Allurion Technologies (NYSE:ALUR) from a hold rating to a strong sell rating in a research report released on Saturday morning.

Separately, Zacks Research raised shares of Allurion Technologies to a “hold” rating in a research note on Tuesday, August 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.83.

Allurion Technologies Stock Down 1.0%

Shares of Allurion Technologies stock opened at $2.38 on Friday. Allurion Technologies has a 12-month low of $2.15 and a 12-month high of $22.25. The firm has a market capitalization of $17.72 million, a PE ratio of -0.19 and a beta of -0.45. The stock’s fifty day moving average is $2.70 and its 200-day moving average is $2.97.

Institutional Trading of Allurion Technologies

An institutional investor recently bought a new position in Allurion Technologies stock. XTX Topco Ltd purchased a new stake in shares of Allurion Technologies, Inc. (NYSE:ALUR) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 13,037 shares of the company’s stock, valued at approximately $42,000. XTX Topco Ltd owned 0.27% of Allurion Technologies at the end of the most recent quarter. 21.39% of the stock is currently owned by institutional investors and hedge funds.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.